Lewy body dementias (DLB/PDD)
Carol F. Lippa
Drexel University College of Medicine, Philadelphia, PA, USA
Search for more papers by this authorKatherine L. Possin
University of California, San Francisco, San Francisco, CA, USA
Search for more papers by this authorCarol F. Lippa
Drexel University College of Medicine, Philadelphia, PA, USA
Search for more papers by this authorKatherine L. Possin
University of California, San Francisco, San Francisco, CA, USA
Search for more papers by this authorMichael D. Geschwind MD PhD
Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Search for more papers by this authorCaroline Racine Belkoura PhD
Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA
Search for more papers by this authorSummary
Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB) are characterized by progressive cognitive decline that involves visuospatial, attentional, and executive dysfunctions; psychiatric disturbances including visual hallucinations, anxiety, apathy, or depression; and a parkinsonian motor syndrome. In PDD, the motor syndrome is established before prominent cognitive decline, whereas in DLB they co-occur or the dementia precedes the motor syndrome. The pathobiology of DLB and PDD is complex but both involve abnormalities of the protein alpha-synuclein. In both conditions, alpha-synuclein aggregates to form Lewy bodies and Lewy neurites. The regional distribution of these inclusions influences the predominance of motor versus cognitive and psychiatric symptoms and signs. As a complicating factor, both vascular and Alzheimer's (AD) pathology are present in many DLB and PDD patients, and the greater the burden of tau pathology, the more clinical features overlap with those of AD. It is still a matter of debate whether the clinical and pathological relationship between DLB and PDD is better characterized as a continuous spectrum rather than dichotomous entities. We review DLB and PDD with an emphasis on clinical features and diagnosis.
References
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Vol. Revised 4th ed. 2000, Washington, DC: American Psychiatric Association.
- Petersen, R.C., et al., Alzheimer's disease neuroimaging initiative (ADNI): clinical characterization. Neurology, 2010. 74(3): pp. 201–9.
- McKeith, I.G., et al., Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology, 2005. 65(12): pp. 1863–72.
- Emre, M., et al., Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord, 2007. 22(12): pp. 1689–707; quiz 1837.
- Aarsland, D., et al., A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry, 2001. 16(5): pp. 528–36.
- Ballard, C., et al., Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. Arch Neurol, 2001. 58(6): pp. 977–82.
- Horimoto, Y., et al., Autonomic dysfunctions in dementia with Lewy bodies. J Neurol, 2003. 250(5): pp. 530–3.
- McKeith, I., et al., Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ, 1992. 305(6855): pp. 673–8.
- Burn, D.J., et al., Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord, 2003. 18(8): pp. 884–9.
- Klein, J.C., et al., Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology. 74(11): pp. 885–92.
- Parkinson, J., An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci, 2002. 14(2): pp. 223–36; discussion 222.
- Okazaki, H., L.E. Lipkin, and S.M. Aronson, Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol, 1961. 20: pp. 237–44.
- Kosaka, K., et al., Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree—a new disease? Clin Neuropathol, 1984. 3(5): pp. 185–92.
- Polymeropoulos, M.H., et al., Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 1997. 276(5321): pp. 2045–7.
- Spillantini, M.G., et al., Alpha-synuclein in Lewy bodies. Nature, 1997. 388(6645): pp. 839–40.
- Lippa, C.F., et al., DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology, 2007. 68(11): pp. 812–9.
- Gilman, S., et al., Second consensus statement on the diagnosis of multiple system atrophy. Neurology, 2008. 71(9): pp. 670–6.
- Kao, A.W., et al., Cognitive and neuropsychiatric profile of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. Alzheimer Dis Assoc Disord, 2009. 23(4): pp. 365–70.
- Elbaz, A., et al., Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol, 2002. 55(1): pp. 25–31.
- de Lau, L.M. and M.M. Breteler, Epidemiology of Parkinson's disease. Lancet Neurol, 2006. 5(6): pp. 525–35.
- Aarsland, D. and M.W. Kurz, The epidemiology of dementia associated with Parkinson's disease. Brain Pathol, 2010. 20(3): pp. 633–9.
- Hely, M.A., et al., The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord, 2008. 23(6): pp. 837–44.
- Aarsland, D., et al., Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord, 2008. 26(5): pp. 445–52.
- Lesage, S. and A. Brice, Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet, 2009. 18(R1): pp. R48–59.
- Boot, B.P., et al., Risk factors for dementia with Lewy bodies: a case-control study. Neurology, 2013. 81(9): pp. 833–40.
- Folstein, M.F., S.E. Folstein, and P.R. McHugh, “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 1975. 12(3): pp. 189–98.
- Gearing, M., et al., The consortium to establish a registry for Alzheimer's disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology, 1995. 45(3 Pt 1): pp. 461–6.
- McKeith, I.G., et al., Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology, 1996. 47(5): pp. 1113–24.
- Aarsland, D., et al., Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease. J Neuropsychiatry Clin Neurosci, 2001. 13(3): pp. 374–9.
- Alves, G., et al., Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord, 2006. 21(8): pp. 1123–30.
- Fahn, S. and R. Elton, Unified Parkinson's disease rating scale, in Recent developments in Parkinson's disease, S. Fahn, D. Marsden, and D. Calne, Editors. 1987, Macmillan: London. pp. 153–63.
- Collerton, D., et al., Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord, 2003. 16(4): pp. 229–37.
- Mosimann, U.P., et al., Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology, 2004. 63(11): pp. 2091–6.
- Troster, A.I., Neuropsychological characteristics of dementia with Lewy bodies and Parkinson's disease with dementia: differentiation, early detection, and implications for “mild cognitive impairment” and biomarkers. Neuropsychol Rev, 2008. 18(1): pp. 103–19.
- Ballard, C.G., et al., Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology, 2002. 59(11): pp. 1714–20.
- Janvin, C.C., et al., Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with Lewy bodies and Alzheimer's disease. Mov Disord, 2006. 21(3): pp. 337–42.
- Perriol, M.P., et al., Disturbance of sensory filtering in dementia with Lewy bodies: comparison with Parkinson's disease dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry, 2005. 76(1): pp. 106–8.
- Calderon, J., et al., Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry, 2001. 70(2): pp. 157–64.
- Tiraboschi, P., et al., What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain, 2006. 129(Pt 3): pp. 729–35.
- Aarsland, D., et al., Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology, 2009. 72(13): pp. 1121–6.
- Cools, R., Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev, 2006. 30(1): pp. 1–23.
- Mattila, P.M., et al., Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol, 2001. 102(2): pp. 160–6.
- Kehagia, A.A., R.A. Barker, and T.W. Robbins, Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol, 2007. 9(12): pp. 1200–1213.
- Williams-Gray, C.H., et al., Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain, 2007. 130(Pt 7): pp. 1787–98.
- Hoops, S., et al., Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology, 2009. 73(21): pp. 1738–45.
- Dalrymple-Alford, J.C., et al., The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology, 75(19): pp. 1717–25.
- Bostrom, F., et al., Patients with dementia with Lewy bodies have more impaired quality of life than patients with Alzheimer disease. Alzheimer Dis Assoc Disord, 2007. 21(2): pp. 150–4.
-
Aarsland, D., et al., Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry, 1999. 14(10): pp. 866–74.
10.1002/(SICI)1099-1166(199910)14:10<866::AID-GPS38>3.0.CO;2-Z CAS PubMed Web of Science® Google Scholar
- Aarsland, D., et al., Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc, 2000. 48(8): pp. 938–42.
- Fritze, F., et al., Depression in mild dementia: associations with diagnosis, APOE genotype and clinical features. Int J Geriatr Psychiatry, 2011. 26(10): pp. 1054–61.
- Shiba, M., et al., Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord, 2000. 15(4): pp. 669–77.
- Dissanayaka, N.N., et al., Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord, 2010. 25(7): pp. 838–45.
- Pedersen, K.F., et al., Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study. J Neurol Neurosurg Psychiatry, 2009. 80(11): pp. 1279–82.
- Ricci, M., et al., Clinical findings, functional abilities and caregiver distress in the early stage of dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Arch Gerontol Geriatr, 2009. 49(2): pp. e101–4.
- Barone, P., Neurotransmission in Parkinson's disease: beyond dopamine. Eur J Neurol, 2010. 17(3): pp. 364–76.
-
Cummings, J.L. and D.L. Masterman, Depression in patients with Parkinson's disease. Int J Geriatr Psychiatry, 1999. 14(9): pp. 711–8.
10.1002/(SICI)1099-1166(199909)14:9<711::AID-GPS4>3.0.CO;2-1 CAS PubMed Web of Science® Google Scholar
- Temel, Y., et al., Parkinson's disease, DBS and suicide: a role for serotonin? Brain, 2009. 132(Pt 10): pp. e126; author reply e127.
- Remy, P., et al., Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain, 2005. 128(Pt 6): pp. 1314–22.
- Lopez, O.L., et al., Lewy bodies in the amygdala increase risk for major depression in subjects with Alzheimer disease. Neurology, 2006. 67(4): pp. 660–5.
- Engelborghs, S., et al., Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. Int J Geriatr Psychiatry, 2005. 20(11): pp. 1028–37.
- Mosimann, U.P., et al., Characteristics of visual hallucinations in Parkinson disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry, 2006. 14(2): pp. 153–60.
- Harding, A.J., G.A. Broe, and G.M. Halliday, Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain, 2002. 125(Pt 2): pp. 391–403.
- Nagahama, Y., et al., Neural correlates of psychotic symptoms in dementia with Lewy bodies. Brain, 2010. 133(Pt 2): pp. 557–67.
- Ballard, C., et al., Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol, 2000. 48(6): pp. 868–76.
- Josephs, K.A., Capgras syndrome and its relationship to neurodegenerative disease. Arch Neurol, 2007. 64(12): pp. 1762–6.
- Boeve, B.F., et al., Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology, 2003. 61(1): pp. 40–5.
- Schenck, C.H., S.R. Bundlie, and M.W. Mahowald, Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology, 1996. 46(2): pp. 388–93.
- Postuma, R.B., et al., Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology, 2009. 72(15): pp. 1296–300.
- Claassen, D.O., et al., REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology. 75(6): pp. 494–9.
- Abbott, R.D., et al., Frequency of bowel movements and the future risk of Parkinson's disease. Neurology, 2001. 57(3): pp. 456–62.
- Abbott, R.D., et al., Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord, 2007. 22(11): pp. 1581–6.
- Ishihara-Paul, L., et al., Prospective association between emotional health and clinical evidence of Parkinson's disease. Eur J Neurol, 2008. 15(11): pp. 1148–54.
- Bower, J.H., et al., Anxious personality predicts an increased risk of Parkinson's disease. Mov Disord. 25(13): pp. 2105–13.
- Boeve, B.F. and C.B. Saper, REM sleep behavior disorder: a possible early marker for synucleinopathies. Neurology, 2006. 66(6): pp. 796–7.
- Fantini, M.L., L. Ferini-Strambi, and J. Montplaisir, Idiopathic REM sleep behavior disorder: toward a better nosologic definition. Neurology, 2005. 64(5): pp. 780–6.
- Menza, M., et al., Sleep disturbances in Parkinson's disease. Mov Disord. 25 Suppl 1: pp. S117–22.
- Boeve, B.F., M.H. Silber, and T.J. Ferman, Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med, 2003. 4(4): pp. 281–4.
- Aarsland, D., et al., Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry, 2005. 66(5): pp. 633–7.
- Litvan, I., et al., Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J Neurol, 1999. 246 Suppl 2: pp. II1–5.
- Lopez, O.L., et al., Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology, 1999. 53(6): pp. 1292–9.
- Merdes, A.R., et al., Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology, 2003. 60(10): pp. 1586–90.
- Isojima, D., et al., Vascular complications in dementia with Lewy bodies: a postmortem study. Neuropathology, 2006. 26(4): pp. 293–7.
- Lee, S.J., et al., Influence of white matter hyperintensities on the cognition of patients with Parkinson disease. Alzheimer Dis Assoc Disord, 2010. 24(3): pp. 227–33.
- Nelson, P.T., et al., Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol 257(3): pp. 359–66.
- Ferman, T.J., et al., DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology, 2004. 62(2): pp. 181–7.
- Burton, E.J., et al., Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain, 2004. 127(Pt 4): pp. 791–800.
- Whitwell, J.L., et al., Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain, 2007. 130(Pt 3): pp. 708–19.
- Cousins, D.A., et al., Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer's disease: an MRI study. Neurology, 2003. 61(9): pp. 1191–5.
- McKeith, I., et al., Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol, 2007. 6(4): pp. 305–13.
- Siderowf, A., et al., CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology, 2010. 75(12): pp. 1055–61.
- Kramer, M.L. and W.J. Schulz-Schaeffer, Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci, 2007. 27(6): pp. 1405–10.
- Baba, M., et al., Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol, 1998. 152(4): pp. 879–84.
- Duda, J.E., et al., Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol, 2002. 52(2): pp. 205–10.
- Samuel, W., et al., Neocortical lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol, 1996. 55(1): pp. 44–52.
- Selikhova, M., et al., A clinico-pathological study of subtypes in Parkinson's disease. Brain, 2009. 132(Pt 11): pp. 2947–57.
- Edison, P., et al., Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry, 2008. 79(12): pp. 1331–8.
- Gomperts, S.N., et al., Imaging amyloid deposition in Lewy body diseases. Neurology, 2008. 71(12): pp. 903–10.
- Lippa, S.M., C.F. Lippa, and H. Mori, Alpha-Synuclein aggregation in pathological aging and Alzheimer's disease: the impact of beta-amyloid plaque level. Am J Alzheimers Dis Other Demen, 2005. 20(5): pp. 315–8.
- Lippa, C.F., R. Johnson, and T.W. Smith, The medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer's disease. Ann Neurol, 1998. 43(1): pp. 102–6.
- Harding, A.J. and G.M. Halliday, Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol, 2001. 102(4): pp. 355–63.
- Alcalay, R.N., et al., Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol. 67(9): pp. 1116–22.
- Wider, C. and Z.K. Wszolek, Etiology and pathophysiology of frontotemporal dementia, Parkinson disease and Alzheimer disease: lessons from genetic studies. Neurodegener Dis, 2008. 5(3–4): pp. 122–5.
- Lippa, C.F., et al., Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol, 1998. 153(5): pp. 1365–70.
- Lippa, C.F., et al., Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol, 1999. 45(3): pp. 353–7.
- Zimprich, A., et al., Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 2004. 44(4): pp. 601–7.
- Lippa, C.F., et al., Alpha-synuclein in familial Alzheimer disease: epitope mapping parallels dementia with Lewy bodies and Parkinson disease. Arch Neurol, 2001. 58(11): pp. 1817–20.
- Frost, B. and M.I. Diamond, The expanding realm of prion phenomena in neurodegenerative disease. Prion, 2009. 3(2): pp. 74–7.
- Frost, B. and M.I. Diamond, Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci, 2010. 11(3): pp. 155–9.
- Yonetani, M., et al., Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J Biol Chem, 2009. 284(12): pp. 7940–50.
- Polymenidou, M. and D.W. Cleveland, Prion-like spread of protein aggregates in neurodegeneration. J Exp Med, 2012. 209(5): pp. 889–93.
- Kordower, J.H., et al., Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med, 2008. 14(5): pp. 504–6.
- Kordower, J.H., et al., Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord, 2008. 23(16): pp. 2303–6.
- Li, J.Y., et al., Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med, 2008. 14(5): pp. 501–3.
- Luk, K.C., et al., Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med, 2012. 209(5): pp. 975–86.
- Luk, K.C., et al., Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science, 2012. 338(6109): pp. 949–53.
- Prusiner, S.B., Biology and genetics of prions causing neurodegeneration. Annu Rev Genet, 2013. 47: pp. 601–23.
- Braak, H., et al., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 2003. 24(2): pp. 197–211.
- Burack, M.A., et al., In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology. 74(1): pp. 77–84.
- Burn, D.J. and J.T. O'Brien, Use of functional imaging in Parkinsonism and dementia. Mov Disord, 2003. 18 Suppl 6: pp. S88–95.
- Bohnen, N.I., et al., Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol, 2003. 60(12): pp. 1745–8.
- Lippa, C.F., T.W. Smith, and E. Perry, Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology. J Neural Transm, 1999. 106(5–6): pp. 525–35.
- Brooks, D.J. and P. Piccini, Imaging in Parkinson's disease: the role of monoamines in behavior. Biol Psychiatry, 2006. 59(10): pp. 908–18.
- El-Agnaf, O.M., et al., Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. Faseb J, 2006. 20(3): pp. 419–25.
- Shimada, H., et al., Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology, 2009. 73(4): pp. 273–8.
- Bohnen, N.I., et al., Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol, 2006. 253(2): pp. 242–7.
- Olin, J.T., D. Aarsland, and X. Meng, Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living. Dement Geriatr Cogn Disord. 29(6): pp. 510–5.
- Wesnes, K.A., et al., Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology, 2005. 65(10): pp. 1654–6.
- Emre, M., et al., Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med, 2004. 351(24): pp. 2509–18.
- McKeith, I., et al., Dementia with Lewy bodies. Lancet Neurol, 2004. 3(1): pp. 19–28.
- Samuel, W., et al., Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry, 2000. 15(9): pp. 794–802.
- Burn, D., et al., Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord, 2006. 21(11): pp. 1899–907.
- Leroi, I., et al., Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord, 2009. 24(8): pp. 1217–21.
- Aarsland, D., et al., Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol, 2009. 8(7): pp. 613–8.
- Boot, B.P., et al., Treatment of dementia with Lewy bodies. Curr Treat Options Neurol, 2013. 15(6): pp. 738–64.
- Kasanuki, K., et al., Effectiveness of ramelteon for treatment of visual hallucinations in dementia with Lewy bodies: a report of 4 cases. J Clin Psychopharmacol, 2013. 33(4): pp. 581–3.
- Amer, D.A., G.B. Irvine, and O.M. El-Agnaf, Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. Exp Brain Res, 2006. 173(2): pp. 223–33.